Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: Past present and future

Heart

Volumn 94, Issue 10, 2008, Pages 1276-1281

  Ommen, S R ^a   Shah, P M ^b   Tajik, A J ^c  

^a MAYO CLINIC   (United States)

^b Hoag Heart Valve Center   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; VERAPAMIL;

AORTA VALVE; BLOOD FLOW; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART PACING; HEART SURGERY; HEART VENTRICLE PACING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; M MODE ECHOCARDIOGRAPHY; MITRAL VALVE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; MUSCLE RESECTION; MYOMECTOMY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOTONIC AGENTS; CATHETER ABLATION; FORECASTING; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MITRAL VALVE; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 52649134379     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2008.154435     Document Type: Review

References (74)

1. Brock RC. Functional obstruction of the left ventricle. Guy's Hasp Rep 1957;106:221-38.
2. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958;20:1-18.
3. Wolstenholme G, O'Connor M, eds. CIBA Foundation symposium: Cardiomyopathies. London: Little, Brown, 1964.
4. Coats CJ, Hollman A. Hypertrophic cardiomyopathy: lessons from history. Heart 2008;94:1258-63.
5. Somerville J. Paul Wood lecture. The master's legacy: the first Paul Wood lecture. Heart 1998;80:612-8; discussion 618-9.
6. Braunwald E, Brockenbrough EC, Frye RL Studies on digitalis. V. Comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis. Circulation 1962;26:166-73.
7. Braunwald E, Ebert P. Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. Am J Cardiol 1962;10:489-94.
8. Braunwald E, Oldham HN Jr, Ross J Jr, et al. The circulatory response of patients with idiopathic hypertrophic subaortic stenosis to nitroglycerin and to the valsalva maneuver. Circulation 1964,29:422-31.
9. Krasnow N, Rolett E, WBJr H, et al. Reversible obstruction of the ventricular outflow tract. Am J Cardiol 1963;11:1-7.
10. Wigle ED, Lenkei SC, Chrysohou A, et al. Muscular subaortic stenosis: the effect of peripheral vasodilatation. Can Med Assoc J 1963;89:896-9.
11. Criley JM, Lewis KB, White Rl Jr, et al. Pressure gradients without obstruction. A new concept of "hypertrophic subaortic stenosis". Circulation 1965;32:881-7.
12. Wigle ED, Heimbecker RO, Gunton RW. Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. Circulation 1962;26:325-40.
13. Wigle ED, Auger P, Marquis Y. Muscular subaortic stenosis: the initial left ventricular inflow tract pressure as evidence of outflow tract obstruction. Can Med Assoc J 1966;95:793-7.
14. Murgo JP, Alter BR, Dorethy JF, et al. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy. J Clin Invest 1980;66:1369-82.
15. Criley JM, Siegel RJ. Has 'obstruction' hindered our understanding of hypertrophic cardiomyopathy? Circulation 1985;72:1148-54.
16. Ross J Jr, Braunwald E, Gault JH, et al. The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation 1966;34:558-78.
17. Shah PM, Gramiak R, Kramer DH. Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation 1969;40:3-11.
18. Sherrid MV, Gunsburg DZ, Moldenhauer S, et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000;36:1344-54.
19. Sherrid MV, Chu CK, Delia E, et al. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:816-25.
20. Maron BJ, Gottdiener JS, Arce J, et al. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985,6:1-18.
21. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-2.
22. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-9.
23. Brockenbrough E, Braunwald E, Morrow A. A hemodynamic technic for the detection of hypertrophic subaortic stenosis. Circulation 1961;23:189-94.
24. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28:1-83.
25. Shah JS, Esteban MTT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008;94:1288-94.
26. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232-9.
27. Braunwald E, Lambrew CD, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients. Circulation 1964;30(suppl IV):3-217.
28. Morrow AG, Lambrew CT, Braunwald E. Idiopathic hypertrophic subaortic stenosis. II. Operative treatment and the results of pre- and postoperative hemodynamic evaluations. Circulation 1964;30(suppl 4):120-51.
29. Brock R. Hypertrophic obstruction of the left ventricular outflow: clinical recognition of the condition. In: Wolstenholme G, O'Connor M, eds. CIBA Foundation Symposium: Cardiomyopathies. London: Little, Brown, 1964:4-10.
30. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Progr Cardiovasc Dis 1985;28:1-83.
31. Jiang L, Levine RA, King ME, et al. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J 1987;113:633- 44.
32. Maron BJ, Ferrans VJ, Henry WL, et al. Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH). Light and electron microscopic findings. Circulation 1974;50:436-46.
33. Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
34. Maron M, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
35. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
36. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-41.
37. Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy related deaths: theory and practice. Heart 2008;94;1269-75.
38. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-6.
39. McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007;28:2583-8.
40. Goodwin J, Shah P, Oakley C, et al. The clinical pharmacology of hypertrophic obstructive cardiomyopathy. In: Wolstenholme G, O'Connor M, eds. CIBA Foundation Symposium: Cardiomyopathies. London: Little, Brown, 1964.
41. Adelman AG, Shah PM, Gramiak R, et al. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 1970:32:804-11.
42. Rosing DR, Condit JR, Maron BJ, et al. Verapamil therapy: a new approach tothe pharmacologic treatment of hypertrophic cardiomyopathy. III. Effects of long-term administration. Am J Cardiol 1981;48:545-53.
43. Rosing DR, Kent KM, Borer JS, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 1979;60:1201-7.
44. Rosing DR, Kent KM, Maron BJ, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 1979;60:1208-13.
45. Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981;64:787-96.
46. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982;307:997-9.
47. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251-8.
48. Fananapazir L, Cannon RO 3rd, Tripodi D, et al. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic Mocker therapy. Circulation 1992;85:2149-61.
49. Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-42.
50. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHYI. Circulation 1999;99:2927- 33.
51. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997:29:435-11.
52. Ommen SR, Nishimura RA, Squires RW, et al. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol 1999;34:191-6.
53. Binder J, Ommen SR, Sorajja P, et al. Clinical and echocardiographic variables fail to predict response to dual-chamber pacing for hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2008;21:796- 800.
54. Dearani JA, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy. Seminars in Thoracic and Cardiovascular Surgery. Pediatric Cardiac Surgery Annual 2005:86-91.
55. Dearani JA, Ommen SR, Gersh BJ, et al. Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopathy - the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 2007;4:503-12.
56. Smedira NG, Lytle BW, Lever HM, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2008;85:127-33.
57. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy [see comment]. Circulation 2005;111:2033-41.
58. Minakata K, Dearani JA, Schaff HV, et al. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 2005;80:851-6.
59. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975;52:88-102.
60. Maron BJ, Merrill WH, Freier PA, et al. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 1978;57:1205-13.
61. Tajik AJ, Giuliani ER, Weidman WH, et al. Idiopathic hypertrophic subaortic stenosis. Long-term surgical follow- up. Am J Cardiol 1974;34:815-22.
62. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
63. Faher L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-21.
64. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-5.
65. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:704-7.
66. Fernandas VL, Nagueh SF, Wang W, et al. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy - the Baylor experience (1996-2002). Clin Cardiol 2005;28:124-30.
67. Firoozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-24.
68. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:1701-6.
69. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38:1994-2000.
70. Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 2005;129:351-8.
71. Faber L, Meissner A, Ziemssen P, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients [see comments]. Heart 2000;83:326-31.
72. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118:131-9.
73. Maron BJ, McKenna W, Danielson GK, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathyl. J Am Coll Cardiol 2003;42:1687-713.
74. Olivotto I, Ommen SR, Maron MS, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol 2007;50:831- 4.